Biolife Story

Biolife Solutions has a beta of -0.3815. Let's try to break down what Biolife's beta means in this case. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Biolife Solutions will likely underperform. The beta indicator helps investors understand whether Biolife Solutions moves in the same direction as the rest of the market, and how volatile (i.e., risky) it is compared to the market (i.e., selected benchmark). In other words, if Biolife deviates very little from the market, it does not add much risk to the portfolio, but it also doesn't increase the expected returns. The entity reported the previous year's revenue of 41.66 M. Net Income was 7.3 M with profit before overhead, payroll, taxes, and interest of 18.9 M.

Biolife Solutions has a good chance to finish above $39 in 2 months

Latest mean deviation is at 2.89. Biolife Solutions exhibits very low volatility with skewness of 0.21 and kurtosis of -0.13. However, we advise investors to further study Biolife Solutions technical indicators to make sure all market info is available and is reliable. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Biolife Solutions' stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Biolife Solutions' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Our Takeaway on Biolife Solutions Investment

While other companies in the medical instruments & supplies industry are either recovering or due for a correction, Biolife Solutions may not be performing as strong as the other in terms of long-term growth potentials. To conclude, as of the 22nd of March 2021, our research shows that Biolife Solutions is a rather very steady investment opportunity with a average chance of distress in the next two years. From a slightly different view, the entity currently appears to be fairly valued. However, our ongoing 30 days 'Buy-vs-Sell' recommendation on the enterprise is Sell.